---
title: "Obefazimod (ABX464) in Ulcerative colitis: ABX464-108"
description: "Formulary evidence on Obefazimod (ABX464) in Ulcerative colitis: ABX464-108. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 41 evidence topics quoted from 6 sources."
canonical: "https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence/abx464-108"
published: "2026-11-18T10:42:55-05:00"
modified: "2026-11-18T10:42:55-05:00"
---

# Obefazimod (ABX464) in Ulcerative colitis: ABX464-108

<a id="heading-3.1.8"></a>

## 3.1.8 ABX464-108

<a id="heading-3.1.8.1"></a>

### 3.1.8.1 Objective

<a id="topic-3.1.8.1-1"></a>

#### Purpose stated in the ClinicalTrials.gov record

> “This study is an open-label study aiming at evaluating the long-term safety and the efficacy profile of ABX464 given once a day (QD) at 25 mg in subjects who have been previously enrolled in the ABX464-102 or ABX464-104 studies (OLE and maintenance studies) and who are willing to continue their treatment.”
> “A Follow-up Phase II Open-label Study to Evaluate the Long-term Safety and Efficacy Profile of ABX464 Given at 25 mg Once Daily in Subjects With Moderate to Severe Active Ulcerative Colitis”
> “To evaluate the long-term safety of ABX464 given at 25 mg once daily in subjects with Moderate to Severe Active Ulcerative Colitis.”

Source: [ClinicalTrials.gov NCT05177835](https://clinicaltrials.gov/study/NCT05177835)

<a id="topic-3.1.8.1-2"></a>

#### Objective of the three-year interim analysis

> “Evaluate maintenance of efficacy through 3 years following dose reduction to obefazimod 25 mg during long-term extension after Phase 2 induction and maintenance studies, overall and by prior advanced therapy exposure”

Source: [Sands et al. (2026b)](https://www.abivax.com/wp-content/uploads/2026/10/OP107_Obe-3yr-LTE-ATIR-OP-DRAFT-07OCT2026-Sands-UEGW2026-ABVX-BES.pdf)

<a id="heading-3.1.8.2"></a>

### 3.1.8.2 Location and Study Date

<a id="topic-3.1.8.2-1"></a>

#### Study dates and status in the ClinicalTrials.gov record

> “Active, not recruiting”
> “Study Start (Actual) 2021-12-03”
> “Primary Completion (Estimated) 2028-03”
> “Study Completion (Estimated) 2028-04”

Source: [ClinicalTrials.gov NCT05177835](https://clinicaltrials.gov/study/NCT05177835)

<a id="topic-3.1.8.2-2"></a>

#### Registered locations

> “This study has 46 locations”

Source: [ClinicalTrials.gov NCT05177835](https://clinicaltrials.gov/study/NCT05177835)

<a id="topic-3.1.8.2-3"></a>

#### Data cutoff of the three-year interim analysis

> “A total of 130 patients entered the trial and as of the January 5, 2026 cutoff date, 80% (104/130) were still enrolled and completed the full 144-week evaluation.”

Source: [Abivax first quarter 2026 results announcement (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-presents-first-quarter-2026-financial-results-and-reports)

> “data transfer date: February 13, 2026”

Source: [UEG Week poster, Study 108 three-year analysis (2026)](https://www.abivax.com/wp-content/uploads/2026/10/Final-Poster-3.-Verstockt-OLE-3-yr-Dose-De-Esc.pdf)

<a id="heading-3.1.8.3"></a>

### 3.1.8.3 Study Design

<a id="topic-3.1.8.3-1"></a>

#### Design details in the ClinicalTrials.gov record

| Field | Quoted record |
| --- | --- |
| Allocation | “N/A” |
| Interventional model | “Single Group Assignment” |
| Interventional model description | “Open Label Follow-up Study” |
| Masking | “None (Open Label)” |
| Phase | “Phase 2” |
| Enrollment (estimated) | “203” |

Source: [ClinicalTrials.gov NCT05177835](https://clinicaltrials.gov/study/NCT05177835)

<a id="topic-3.1.8.3-2"></a>

#### Treatment period and follow-up in the ClinicalTrials.gov record

> “Subjects will be treated with ABX464 for a maximum period of 54 months. Subjects will be followed up quarterly. After the treatment period, subjects will be followed for 4 additional weeks for safety purposes.”
> “From Baseline to a maximum period of 78 months”

Source: [ClinicalTrials.gov NCT05177835](https://clinicaltrials.gov/study/NCT05177835)

<a id="topic-3.1.8.3-3"></a>

#### Dose de-escalation after the phase 2a and phase 2b open-label maintenance studies

> “patients who had completed the four-year Phase 2a or two-year Phase 2b OLM trials, where they had received 50 mg of once-daily obefazimod, were given the opportunity to continue receiving obefazimod at a reduced dose of 25 mg daily for up to five additional years (provided they met the eligibility criteria of Mayo Endoscopic Subscore = 0 or 1).”

Source: [Abivax first quarter 2026 results announcement (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-presents-first-quarter-2026-financial-results-and-reports)

<a id="topic-3.1.8.3-4"></a>

#### Design described in the congress poster

> “Patients with UC received Obe 50 mg in the Phase 2 trials for 2 to 4 years; those who achieved endoscopic improvement (Mayo Endoscopic subscore = 0 or 1 and rectal bleeding subscore = 0) were eligible to enroll in an OLM study (Fig 1)”
> “Patients enrolled can receive Obe 25 mg for up to an additional 78 months”

Source: [UEG Week poster, Study 108 three-year analysis (2026)](https://www.abivax.com/wp-content/uploads/2026/10/Final-Poster-3.-Verstockt-OLE-3-yr-Dose-De-Esc.pdf)

<a id="topic-3.1.8.3-5"></a>

#### Phase 2 program schema

> “Obefazimod 50 mg (n=22)”
> “48 months ~4 years of treatment”
> “Obefazimod 50 mg (n=217)”
> “48 + 48 weeks ~2 years of treatment”
> “Up to 78 months”

Source: [Sands et al. (2026b)](https://www.abivax.com/wp-content/uploads/2026/10/OP107_Obe-3yr-LTE-ATIR-OP-DRAFT-07OCT2026-Sands-UEGW2026-ABVX-BES.pdf)

<a id="heading-3.1.8.4"></a>

### 3.1.8.4 Eligibility Criteria

<a id="topic-3.1.8.4-1"></a>

#### Inclusion and exclusion criteria in the ClinicalTrials.gov record

> “Subjects who previously completed the ABX464-102 or ABX464-104 clinical studies”
> “Subjects should be in endoscopic improvement with a rectal bleeding sub-score = 0 point at the end of treatment period in the previous study (ABX464-102 or ABX464-104). Endoscopic improvement is defined as: a Mayo endoscopic sub score of ≤1 ;”
> “Subjects who have developed any major illness/condition or evidence of an unstable clinical condition (except UC) that, in the investigator's judgment, will substantially increase the risk to the participant if he or she participates in the study”
> “18 Years and older (Adult, Older Adult )”

Source: [ClinicalTrials.gov NCT05177835](https://clinicaltrials.gov/study/NCT05177835)

<a id="topic-3.1.8.4-2"></a>

#### Eligibility criteria shown in the congress presentation

> “Mayo Endoscopic subscore = 0 or 1 AND Rectal bleeding subscore = 0”

Source: [Sands et al. (2026b)](https://www.abivax.com/wp-content/uploads/2026/10/OP107_Obe-3yr-LTE-ATIR-OP-DRAFT-07OCT2026-Sands-UEGW2026-ABVX-BES.pdf)

<a id="heading-3.1.8.5"></a>

### 3.1.8.5 Treatment

<a id="topic-3.1.8.5-1"></a>

#### Intervention in the ClinicalTrials.gov record

> “All subjects will receive ABX464 given at 25 mg QD.”

Source: [ClinicalTrials.gov NCT05177835](https://clinicaltrials.gov/study/NCT05177835)

<a id="topic-3.1.8.5-2"></a>

#### Prior obefazimod 50 mg exposure

> “Patients with UC received Obe 50 mg for approximately four years in the Phase 2a OLM study and for approximately two years in the Phase 2b OLM study”

Source: [UEG Week poster, Study 108 three-year analysis (2026)](https://www.abivax.com/wp-content/uploads/2026/10/Final-Poster-3.-Verstockt-OLE-3-yr-Dose-De-Esc.pdf)

<a id="topic-3.1.8.5-3"></a>

#### Total duration of obefazimod treatment

> “Patients in Study 108 were treated with obefazimod for up to seven years, with no new safety signals observed”

Source: [Abivax first quarter 2026 results announcement (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-presents-first-quarter-2026-financial-results-and-reports)

<a id="heading-3.1.8.6"></a>

### 3.1.8.6 Study Outcomes

<a id="heading-3.1.8.6.1"></a>

#### 3.1.8.6.1 Rationale for Using Adverse Events as the Primary Endpoint

<a id="topic-3.1.8.6.1-1"></a>

##### Registered primary and secondary outcome measures

> “Number of adverse events in ABX464 treated subjects”
> “Percentage of subjects reaching clinical remission at yearly visits.”
> “Percentage of subjects reaching endoscopic remission at yearly visits”
> “Percentage of subjects reaching clinical response at yearly visits”
> “Percentage of subjects reaching endoscopic improvement at yearly visits”

Source: [ClinicalTrials.gov NCT05177835](https://clinicaltrials.gov/study/NCT05177835)

<a id="topic-3.1.8.6.1-2"></a>

##### Efficacy endpoint definitions in the interim analysis

> “Clinical remission: SFS = 0 or 1, RBS = 0, and MES = 0 or 1. Symptomatic remission: SFS = 0 or 1 and RBS = 0. Endoscopic improvement: MES = 0 or 1. Endoscopic remission: MES = 0.”

Source: [Sands et al. (2026b)](https://www.abivax.com/wp-content/uploads/2026/10/OP107_Obe-3yr-LTE-ATIR-OP-DRAFT-07OCT2026-Sands-UEGW2026-ABVX-BES.pdf)

<a id="heading-3.1.8.7"></a>

### 3.1.8.7 Statistical Analysis Description

<a id="heading-3.1.8.7.1"></a>

#### 3.1.8.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.8.7.1-1"></a>

##### Planned enrollment

> “Enrollment (Estimated) 203”

Source: [ClinicalTrials.gov NCT05177835](https://clinicaltrials.gov/study/NCT05177835)

<a id="topic-3.1.8.7.1-2"></a>

##### Participants eligible and treated

> “Out of 174 pts who completed these studies (10 in Phase 2a OLM, 164 in Phase 2b OLM), 138 were eligible”
> “Overall, 130 pts received treatment in the Obe-25 OLM”

Source: [UEG Week poster, Study 108 three-year analysis (2026)](https://www.abivax.com/wp-content/uploads/2026/10/Final-Poster-3.-Verstockt-OLE-3-yr-Dose-De-Esc.pdf)

<a id="topic-3.1.8.7.1-3"></a>

##### Participants analyzed in the congress presentation

| Analysis | Quoted record |
| --- | --- |
| Safety, all participants | “n = 130” |
| Week 144 completers | “n=104” |
| Week 144 completers naive to advanced therapy inadequate response | “57” |
| Week 144 completers with prior advanced therapy inadequate response | “47” |

Source: [Sands et al. (2026b)](https://www.abivax.com/wp-content/uploads/2026/10/OP107_Obe-3yr-LTE-ATIR-OP-DRAFT-07OCT2026-Sands-UEGW2026-ABVX-BES.pdf)

<a id="topic-3.1.8.7.1-4"></a>

##### Participants evaluated at the September 2024 data cutoff

> “A total of 130 patients entered the trial, as of September 11, 2024, the data cut-off date, 113 patients have been evaluated out to 48 weeks and 74 patients have undergone the full 96-week evaluation.”

Source: [Abivax Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm)

<a id="heading-3.1.8.7.2"></a>

#### 3.1.8.7.2 Description of Analysis Sets

<a id="topic-3.1.8.7.2-1"></a>

##### Intent-to-treat analysis with non-responder imputation

> “Clinical remission, inclusive of endoscopic subscore, was evaluated in the ITT population using non-responder imputation.”

Source: [Abivax first quarter 2026 results announcement (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-presents-first-quarter-2026-financial-results-and-reports)

<a id="topic-3.1.8.7.2-2"></a>

##### Non-responder imputation and as-observed analyses

> “This interim analysis (data transfer date: February 13, 2026) reports efficacy outcomes through the Week 144 visit (clinical remission, endoscopic improvement, endoscopic remission, and symptomatic remission), using both a non-responder imputation and as observed analysis”
> “Treatment emergent adverse events (TEAEs), serious TEAEs, and study discontinuation rates were examined”

Source: [UEG Week poster, Study 108 three-year analysis (2026)](https://www.abivax.com/wp-content/uploads/2026/10/Final-Poster-3.-Verstockt-OLE-3-yr-Dose-De-Esc.pdf)

<a id="topic-3.1.8.7.2-3"></a>

##### Week 144 completer population and definition of prior advanced therapy inadequate response

> “Here we present efficacy and safety in patients completing Week 144 of 25 mg treatment stratified by prior inadequate response to advanced therapies”
> “primary refractoriness to biologics or JAK inhibitors”

Source: [Sands et al. (2026b)](https://www.abivax.com/wp-content/uploads/2026/10/OP107_Obe-3yr-LTE-ATIR-OP-DRAFT-07OCT2026-Sands-UEGW2026-ABVX-BES.pdf)

<a id="heading-3.1.8.8"></a>

### 3.1.8.8 Results

<a id="heading-3.1.8.8.1"></a>

#### 3.1.8.8.1 Participant Disposition

<a id="topic-3.1.8.8.1-1"></a>

##### Discontinuations and visit completion through week 144

> “Among this cohort, 16 pts (12%) discontinued prior to W48, including 4 who were subsequently found to be ineligible after enrollment”
> “7 pts (5%) discontinued between W48 and W96; and 3 pts (2%) discontinued between W96 and W144”
> “As of the data transfer date, 113 pts (87%) completed the W48 visit, 107 (82%) the W96 visit and 104 (80%) the W144 visit”

Source: [UEG Week poster, Study 108 three-year analysis (2026)](https://www.abivax.com/wp-content/uploads/2026/10/Final-Poster-3.-Verstockt-OLE-3-yr-Dose-De-Esc.pdf)

<a id="topic-3.1.8.8.1-2"></a>

##### Participants at each timepoint in the program schema

| Timepoint | Quoted record |
| --- | --- |
| Week 48 | “n= 114” |
| Week 96 | “n=107” |
| Completed week 144 | “n=104” |

Source: [Sands et al. (2026b)](https://www.abivax.com/wp-content/uploads/2026/10/OP107_Obe-3yr-LTE-ATIR-OP-DRAFT-07OCT2026-Sands-UEGW2026-ABVX-BES.pdf)

<a id="topic-3.1.8.8.1-3"></a>

##### Retention reported by the sponsor

> “Following two to four years of open-label treatment with 50 mg, 130 patients de-escalated to 25 mg, and at week 144, 68% (88/130) were in clinical remission and 80% (104/130) completed 144 weeks of treatment”

Source: [Abivax first quarter 2026 results announcement (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-presents-first-quarter-2026-financial-results-and-reports)

<a id="topic-3.1.8.8.1-4"></a>

##### Retention at the September 2024 data cutoff

> “Patient retention rates were high, with only 12% (16/130) of patients discontinuing in the first year and 5% (6/114) discontinuing during the second year of treatment.”

Source: [Abivax Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm)

<a id="heading-3.1.8.8.2"></a>

#### 3.1.8.8.2 Baseline Characteristics

<a id="topic-3.1.8.8.2-1"></a>

##### Clinical remission at study baseline

> “At study baseline, 89% (116/130) of patients were in clinical remission.”

Source: [Abivax first quarter 2026 results announcement (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-presents-first-quarter-2026-financial-results-and-reports)

<a id="topic-3.1.8.8.2-2"></a>

##### Characteristics at the start of the 25 mg dose among week 144 completers

| Characteristic | Week 144 completers (n=104) |
| --- | --- |
| Age, years, mean (SD) | “45.4 (12.74)” |
| Male, n (%) | “65 (62.5)” |
| UC duration, years, mean (SD) | “11.2 (7.02)” |
| Modified Mayo score 0 to 4, n (%) | “104 (100)” |
| C-reactive protein, mg/L, median | “2.2” |
| Fecal calprotectin, µg/g, median | “57.0” |
| Concomitant corticosteroids, n (%) | “6 (5.8)” |
| Concomitant 5-ASA, n (%) | “79 (76.0)” |
| Prior refractoriness to biologics, n (%) | “49 (47.1)” |
| Primary non-response, n (%) | “19 (38.8)” |
| Loss of response, n (%) | “30 (61.2)” |

Source: [Sands et al. (2026b)](https://www.abivax.com/wp-content/uploads/2026/10/OP107_Obe-3yr-LTE-ATIR-OP-DRAFT-07OCT2026-Sands-UEGW2026-ABVX-BES.pdf)

<a id="heading-3.1.8.8.3"></a>

#### 3.1.8.8.3 Efficacy Results

<a id="topic-3.1.8.8.3-1"></a>

##### Clinical remission at weeks 48, 96, and 144 with non-responder imputation

> “At weeks 48, 96 and 144 of treatment, 73% (95/130), 69% (90/130), and 68% (88/130) of patients evaluated were in clinical remission, respectively.”
> “Similar trends were observed with other efficacy analyses, and no new safety signals were observed.”

Source: [Abivax first quarter 2026 results announcement (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-presents-first-quarter-2026-financial-results-and-reports)

<a id="topic-3.1.8.8.3-2"></a>

##### Clinical and symptomatic remission in the non-responder imputation and as-observed analyses

> “Following treatment with Obe-25, rates of clinical remission were 73% at W48, 69% at W96 and 68% at W144, while symptomatic remission rates ranged from 72% to 79% (NRI analysis)”
> “In the as-observed analysis among Week 144 completers, clinical remission rates were 84-85% through W144, while symptomatic remission rates ranged from 89% to 91%.”

Source: [UEG Week poster, Study 108 three-year analysis (2026)](https://www.abivax.com/wp-content/uploads/2026/10/Final-Poster-3.-Verstockt-OLE-3-yr-Dose-De-Esc.pdf)

<a id="topic-3.1.8.8.3-3"></a>

##### Efficacy endpoints among week 144 completers

| Endpoint (n=104) | Baseline | Week 48 | Week 96 | Week 144 |
| --- | --- | --- | --- | --- |
| Clinical remission | “91%” | “85%” | “85%” | “85%” |
| Symptomatic remission | “92%” | “90%” | “88%” | “90%” |
| Endoscopic improvement | “99%” | “92%” | “93%” | “92%” |
| Endoscopic remission | “66%” | “66%” | “72%” | “72%” |

Source: [Sands et al. (2026b)](https://www.abivax.com/wp-content/uploads/2026/10/OP107_Obe-3yr-LTE-ATIR-OP-DRAFT-07OCT2026-Sands-UEGW2026-ABVX-BES.pdf)

<a id="topic-3.1.8.8.3-4"></a>

##### Efficacy endpoints among week 144 completers by prior advanced therapy inadequate response

| Endpoint and subgroup | Baseline | Week 48 | Week 96 | Week 144 |
| --- | --- | --- | --- | --- |
| Clinical remission, AT-IR naive (N=57) | “97%” | “91%” | “88%” | “90%” |
| Clinical remission, prior AT-IR (N=47) | “85%” | “77%” | “80%” | “79%” |
| Symptomatic remission, AT-IR naive (N=57) | “97%” | “97%” | “91%” | “95%” |
| Symptomatic remission, prior AT-IR (N=47) | “87%” | “83%” | “85%” | “85%” |
| Endoscopic improvement, AT-IR naive (N=57) | “100%” | “93%” | “95%” | “95%” |
| Endoscopic improvement, prior AT-IR (N=47) | “98%” | “92%” | “91%” | “89%” |
| Endoscopic remission, AT-IR naive (N=57) | “84%” | “77%” | “84%” | “81%” |
| Endoscopic remission, prior AT-IR (N=47) | “45%” | “53%” | “57%” | “62%” |

Source: [Sands et al. (2026b)](https://www.abivax.com/wp-content/uploads/2026/10/OP107_Obe-3yr-LTE-ATIR-OP-DRAFT-07OCT2026-Sands-UEGW2026-ABVX-BES.pdf)

<a id="topic-3.1.8.8.3-5"></a>

##### Fecal calprotectin through week 144

> “Median fecal calprotectin (FCP) ranged from 48 to 98 µg/g over the 144-week study period”
> “Among pts with available FCP data at W144, 81% (72/89) had FCP levels <250 µg/g and 69% (61/89) had levels <150 µg/g (Fig 3)”

Source: [UEG Week poster, Study 108 three-year analysis (2026)](https://www.abivax.com/wp-content/uploads/2026/10/Final-Poster-3.-Verstockt-OLE-3-yr-Dose-De-Esc.pdf)

<a id="topic-3.1.8.8.3-6"></a>

##### Two-year interim analysis among participants evaluated, September 2024 data cutoff

> “At study baseline, 89% (116/130) of patients were in clinical remission. At weeks 48 and 96 of treatment, 84% (95/113) and 87% (64/74) of patients evaluated were in clinical remission, respectively. Similarly, 92% (119/130) of patients were in symptomatic remission at study baseline. At weeks 48 and 96, 91% (103/113) and 92% (68/74) of patients evaluated were in symptomatic remission, respectively.”

Source: [Abivax Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm)

<a id="heading-3.1.8.8.4"></a>

#### 3.1.8.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.8.8.5"></a>

#### 3.1.8.8.5 Safety Results

<a id="topic-3.1.8.8.5-1"></a>

##### Treatment-emergent adverse events in all 130 participants

| Event | N (%) [IR/100 PY] |
| --- | --- |
| Any TEAE | “96 (73.8) [87.9]” |
| TEAE leading to discontinuation | “9 (6.9) [4.25]” |
| Serious TEAE | “8 (6.2) [3.86]” |
| Ulcerative colitis | “15 (11.5) [7.3]” |
| Nasopharyngitis | “11 (8.5) [5.4]” |
| Upper respiratory tract infection | “10 (7.7) [4.9]” |
| COVID-19 | “11 (8.5) [5.4]” |
| Hypertension | “7 (5.4) [3.4]” |
| Diarrhea | “5 (3.8) [2.4]” |
| Arthralgia | “5 (3.8) [2.4]” |
| Gastroenteritis | “4 (3.1) [1.9]” |
| Non-melanoma skin cancer | “1 (0.8) [0.5]” |

Source: [Sands et al. (2026b)](https://www.abivax.com/wp-content/uploads/2026/10/OP107_Obe-3yr-LTE-ATIR-OP-DRAFT-07OCT2026-Sands-UEGW2026-ABVX-BES.pdf)

<a id="topic-3.1.8.8.5-2"></a>

##### Deaths, opportunistic infections, and laboratory findings

> “Death 0 Opportunistic infections 0”
> “This table does not include laboratory findings.”

Source: [Sands et al. (2026b)](https://www.abivax.com/wp-content/uploads/2026/10/OP107_Obe-3yr-LTE-ATIR-OP-DRAFT-07OCT2026-Sands-UEGW2026-ABVX-BES.pdf)

<a id="topic-3.1.8.8.5-3"></a>

##### Infections and malignancies across up to 7 years of treatment

> “No safety signals were identified over the 144-week period”
> “Across up to 7 years of treatment, no safety signal for infections or malignancies emerged”

Source: [UEG Week poster, Study 108 three-year analysis (2026)](https://www.abivax.com/wp-content/uploads/2026/10/Final-Poster-3.-Verstockt-OLE-3-yr-Dose-De-Esc.pdf)

<a id="topic-3.1.8.8.5-4"></a>

##### Safety at the September 2024 data cutoff

> “The safety results were consistent with previous trials, with no new safety signals detected.”

Source: [Abivax Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm)

<a id="heading-3.1.8.9"></a>

### 3.1.8.9 Study Limitations

<a id="topic-3.1.8.9-1"></a>

#### Summary

ABX464-108 (Study 108) is an ongoing single-group, open-label extension without a control group, in which participants who completed the phase 2a (ABX464-102) or phase 2b (ABX464-104) open-label maintenance studies on obefazimod 50 mg, and who had a Mayo endoscopic subscore of 0 or 1 and a rectal bleeding subscore of 0, received obefazimod 25 mg once daily. Entry selected participants already in endoscopic improvement after 2 to 4 years of treatment: of 174 who completed the earlier studies, 138 were eligible and 130 were treated, and 89% (116/130) were in clinical remission at study baseline. The study has no randomized comparison of 25 mg with continued 50 mg. Results come from an interim analysis presented at a congress and in a press release (January 5, 2026 cutoff; February 13, 2026 data transfer); no peer-reviewed report or registry results exist, and primary completion is estimated for March 2028. Clinical remission by non-responder imputation was 73%, 69%, and 68% at weeks 48, 96, and 144. The baseline characteristics and the subgroup analyses by prior advanced therapy inadequate response were reported only for the 104 participants who completed week 144, among whom clinical remission was 84% to 85% in the as-observed analysis. Sources state the treatment period differently: a maximum of 54 months in the registry summary, 78 months in the registry outcome time frame and the poster, and up to five additional years in the press release. The number completing week 48 is 113 in the poster and 114 on a presentation slide, and the number completing the phase 2a extension is 10 in the poster and 11 in the posted ABX464-102 results. The safety table excludes laboratory findings. No health-related quality of life results were located.

Source: [ClinicalTrials.gov NCT05177835](https://clinicaltrials.gov/study/NCT05177835); [Abivax first quarter 2026 results announcement (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-presents-first-quarter-2026-financial-results-and-reports); [UEG Week poster, Study 108 three-year analysis (2026)](https://www.abivax.com/wp-content/uploads/2026/10/Final-Poster-3.-Verstockt-OLE-3-yr-Dose-De-Esc.pdf); [Sands et al. (2026b)](https://www.abivax.com/wp-content/uploads/2026/10/OP107_Obe-3yr-LTE-ATIR-OP-DRAFT-07OCT2026-Sands-UEGW2026-ABVX-BES.pdf); [ClinicalTrials.gov NCT03368118 results](https://clinicaltrials.gov/study/NCT03368118?tab=results)

## Related pages
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Terms and abbreviations](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations.md)
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Product information and disease description](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Clinical evidence](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Economic information and modeling report](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics.md)
- [Obefazimod (ABX464) in Ulcerative colitis: References](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references.md)
